Type I error probability spending for post-market drug and vaccine safety surveillance with Poisson data
From MaRDI portal
Publication:1657816
DOI10.1007/s11009-017-9586-zzbMath1395.62244OpenAlexW2742496407WikidataQ92340072 ScholiaQ92340072MaRDI QIDQ1657816
Publication date: 14 August 2018
Published in: Methodology and Computing in Applied Probability (Search for Journal in Brave)
Full work available at URL: http://europepmc.org/articles/pmc6936745
Applications of statistics to biology and medical sciences; meta analysis (62P10) Sequential statistical analysis (62L10) Optimal stopping in statistics (62L15)
Related Items (3)
Frequentist-Bayesian Monte Carlo testing ⋮ Exact conditional maximized sequential probability ratio test adjusted for covariates ⋮ Complementary hypotheses in safety surveillance
Uses Software
Cites Work
- Unnamed Item
- Unnamed Item
- A Maximized Sequential Probability Ratio Test for Drug and Vaccine Safety Surveillance
- Statistical approaches to interim monitoring of medical trials: A review and commentary
- Continuous versus group sequential analysis for post-market drug and vaccine safety surveillance
- Discrete Sequential Boundaries for Clinical Trials
- Design and analysis of group sequential tests based on the type I error spending rate function
- Efficient Score Statistic in Drug and Vaccine Safety Surveillance
- Sequential Tests of Statistical Hypotheses
This page was built for publication: Type I error probability spending for post-market drug and vaccine safety surveillance with Poisson data